The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms
Open accessAbstract
Background: A growing body of evidence suggests that atrial fibrillation ( AF ) is associated with myocardial infarction ( MI ). However, incidence and management of MI in AF is still undefined. Methods and Results: We searched MEDLINE via PubMed and Cochrane database between 1965 and 2015. All observational clinical studies and interventional trials reporting 1‐year incidence of MI in AF were included. We also discussed pathophysiological mechanisms, predictors, and therapeutic approaches to reduce the risk of MI in AF . Twenty‐one observational studies and 10 clinical trials were included. The annual rate of MI in observational studies including AF patients ranged from 0.4% to 2.5%. Higher rates of MI were reported in AF patients with stable coronary artery disease (11.5%/year), vascular disease (4.47%/year), heart failure (2.9%/year), and in those undergoing coronary artery interventions (6.3%/year). However, lower annual rates have been described in AF patients from Eastern countries (0.2–0.3%/year), and in those enrolled in clinical trials (from 0.4 to 1.3%/year). Conclusions: AF patients had a significant residual risk of MI despite anticoagulant treatment. Coexistence of atherosclerotic risk factors and platelet activation account for the increased risk of MI in AF . Identification of high‐risk AF patients is a needed first step to develop cost‐effective approaches for prevention. A new score, the 2 MACE score, has been recently developed to stratify MI risk in AF , and may help not only in allocating resources to high‐risk groups, but also in design of studies examining novel therapies for prevention of MI in AF .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62343-0 · Cited by 5,051 · cited 1×
“Warfarin and NOACs are equivalent in terms of cerebrovascular events reduction, but NOACs have been associated with less risk of bleeding.(3) In addition to thromboembolism, AF is characterized by a constellation of atherosclerotic risk factors including hypertension, diabetes, metabolic syndrome, and dyslipidemia and…”
BackgroundThe Metabolic Syndrome and Cardiovascular Risk
Mottillo, S., Filion, K. B., Genest, J., Joseph, L., Pilote, L., Poirier, P., Rinfret, S., Schiffrin, E. L., & Eisenberg, M. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.034 · Cited by 3,009
Apixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study
Heeringa, J., van der Kuip, D. A. M., Hofman, A., Kors, J. A., van Herpen, G., Stricker, B. H. C., Stijnen, T., Lip, G. Y. H., & Witteman, J. C. M. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi825 · Cited by 1,939 · cited 2×
“Aging has a negative impact not only for the occurrence of AF but also for ischemic stroke, which sharply increases in the elderly population as well.(1) Consequently, the clinical history of most AF patients is often complicated by thromboembolic events; for this reason AF patients are treated with oral anticoagulant…”
BackgroundStatins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Fowkes, F. G. R. (2010) · JAMA · doi:10.1001/jama.2010.221 · Cited by 624
Watanabe, H., Tanabe, N., Watanabe, T., Darbar, D., Roden, D. M., Sasaki, S., & Aizawa, Y. (2008) · Circulation · doi:10.1161/circulationaha.107.744466 · Cited by 427
Kirchhof, P., Ammentorp, B., Darius, H., De Caterina, R., Le Heuzey, J.-Y., Schilling, R. J., Schmitt, J., & Zamorano, J. L. (2014) · EP Europace · doi:10.1093/europace/eut263 · Cited by 404 · cited 1×
“This is in keeping with findings from recent surveys reporting that at least 15% to 30% of AF patients are treated only with aspirin, or do not receive any antithrombotic treatment.(37,38) MI rate is also influenced by sex, with females being at higher risk of MI compared to men, as shown in the REGARDS study.”
ResultVermond, R. A., Geelhoed, B., Verweij, N., Tieleman, R. G., Van der Harst, P., Hillege, H. L., Van Gilst, W. H., Van Gelder, I. C., & Rienstra, M. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.1314 · Cited by 297
Davı̀, G., Gresele, P., Violi, F., Basili, S., Catalano, M., Giammarresi, C., Volpato, R., Nenci, G. G., Ciabattoni, G., & Patrono, C. (1997) · Circulation · doi:10.1161/01.cir.96.1.69 · Cited by 223
Self-citationSoliman, E. Z., Lopez, F., O’Neal, W. T., Chen, L. Y., Bengtson, L., Zhang, Z.-M., Loehr, L., Cushman, M., & Alonso, A. (2015) · Circulation · doi:10.1161/circulationaha.114.014145 · Cited by 174
Self-citationAndersson, T., Magnuson, A., Bryngelsson, I.-L., Frøbert, O., Henriksson, K. M., Edvardsson, N., & Poçi, D. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.09.092 · Cited by 68
Goto, S., Ikeda, Y., Shimada, K., Uchiyama, S., Origasa, H., Kobayashi, H., & The J-TRACE Investigators (2011) · Circulation Journal · doi:10.1253/circj.cj-11-0378 · Cited by 35
Cited by
Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes
Staerk, L., Sherer, J. A., Ko, D., Benjamin, E. J., & Helm, R. H. (2017) · Circulation Research · doi:10.1161/circresaha.117.309732 · Cited by 1,201
Carnethon, M. R., Pu, J., Howard, G., Albert, M. A., Anderson, C. A. M., Bertoni, A. G., Mujahid, M. S., Palaniappan, L., Taylor, H. A., Willis, M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000534 · Cited by 1,147
Pastori, D., Carnevale, R., Nocella, C., Novo, M., Santulli, M., Cammisotto, V., Menichelli, D., Pignatelli, P., & Violi, F. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005784 · Cited by 182
“Atrial fibrillation (AF) is themost common cardiac arrhythmia and is complicated by cardiovascular events of thromboembolic and atherothrombotic origin such as ischemic stroke, peripheral embolism, andmyocardial infarction.(16) Taking into account that LPS may play a role not only in the atherosclerotic process but al…”
BackgroundSelf-citationLee, T.-W., Lee, T.-I., Lin, Y.-K., Chen, Y.-C., Kao, Y.-H., & Chen, Y.-J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03648-y · Cited by 27
Metadata
- Authors
- Violi, F., Soliman, E. Z., Pignatelli, P., & Pastori, D.
- Venue
- Journal of the American Heart Association
- Published
- 2016-05-06
- Volume
- 5
- Issue
- 5
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2399636953
- Cited by
- 200
- References
- 20
- FWCI
- 5.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.